Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL18261569 | 0.98 | MGLL (0.59) | MGLLPTGS1PTGS2FAAHDRD2 | |
| SCHEMBL7943421 | 0.85 | MGLL (0.76) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4967709 | 0.84 | MGLL (0.47) | MGLLPTGS1PTGS2FAAHDRD2 | |
| Trifluoroacetic Acid SCHEMBL247137 | 0.84 | PTGS1 (0.44) | MGLLPTGS1PTGS2FAAHDRD2 | |
| SCHEMBL24797392 | 0.84 | MGLL (0.80) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL13755287 | 0.84 | MGLL (0.80) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL22311910 | 0.84 | MGLL (0.80) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL22311931 | 0.84 | MGLL (0.80) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL16006807 | 0.84 | MGLL (0.80) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL20026448 | 0.84 | MGLL (0.80) | MGLLPTGS1PTGS2FAAHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479933-B2 | Crosslinked alginic acid structure | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2025-11-25 | — | — | US | disclosed |
| EP-3778653-B1 | NOVEL REACTIVE ALGINIC ACID DERIVATIVES | MOCHIDA PHARM CO LTD (JP) | 2025-07-09 | — | — | EP | disclosed |
| CN-114521199-B | Cross-linked alginic acid structure | 持田制药株式会社 | 2025-05-30 | — | — | CN | disclosed |
| US-20220396643-A1 | NOVEL CROSSLINKED ALGINIC ACID STRUCTURE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2022-12-15 | — | — | US | disclosed |
| US-11472892-B2 | Reactive alginic acid derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2022-10-18 | — | — | US | disclosed |
| EP-4035735-A1 | NOVEL CROSSLINKED ALGINIC ACID STRUCTURE | Mochida Pharmaceutical Co., Ltd. (JP) | 2022-08-03 | — | — | EP | disclosed |
| CN-111868096-B | Reactive alginic acid derivatives | 持田制药株式会社 | 2022-06-17 | — | — | CN | disclosed |
| CN-114521199-A | Novel cross-linked alginic acid structure | 持田制药株式会社 | 2022-05-20 | — | — | CN | disclosed |
| US-11141489-B2 | Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acid | SANOFI (FR) | 2021-10-12 | — | — | US | disclosed |
| EP-3778653-A1 | NOVEL REACTIVE ALGINIC ACID DERIVATIVES | Mochida Pharmaceutical Co., Ltd. (JP) | 2021-02-17 | — | — | EP | disclosed |
| US-9352049-B2 | Ligand-therapeutic agent conjugates, silicon-based linkers, and methods for making and using them | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2968599-A1 | LIGAND-THERAPEUTIC AGENT CONJUGATES AND SILICON-BASED LINKERS | Albany Molecular Research, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20140322247-A1 | CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2014-10-30 | — | — | US | disclosed |
| WO-2014160305-A1 | LIGAND-THERAPEUTIC AGENT CONJUGATES AND SILICON-BASED LINKERS | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140274951-A1 | LIGAND-THERAPEUTIC AGENT CONJUGATES, SILICON-BASED LINKERS, AND METHODS FOR MAKING AND USING THEM | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140186875-A1 | NOVEL OPTICAL LABELING MOLECULES FOR PROTEOMICS AND OTHER BIOLOGICAL ANALYSIS | MONTANA STATE UNIVERSITY (US) | 2014-07-03 | — | — | US | disclosed |
| US-20100252433-A1 | NOVEL OPTICAL LABELING MOLECULES FOR PROTEOMICS AND OTHER BIOLOGICAL ANALYSES | NATIONAL SCIENCE FOUNDATION | 2010-10-07 | — | — | US | disclosed |
| EP-2164997-A2 | NOVEL OPTICAL LABELING MOLECULES IN PROTEOMICS AND OTHER BIOLOGICAL ANALYSES | Montana State University (US) | 2010-03-24 | — | — | EP | disclosed |
| WO-2009005871-A2 | NOVEL OPTICAL LABELING MOLECULES IN PROTEOMICS AND OTHER BIOLOGICAL ANALYSES | MONTANA STATE UNIVERSITY (US) | 2009-01-08 | — | — | WO | disclosed |
| US-5053503-A | For joining antibodies and metallic radionuclides | CENTOCOR (US) | 1991-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100252433-A1 | NOVEL OPTICAL LABELING MOLECULES FOR PROTEOMICS AND OTHER BIOLOGICAL ANALYSES | PTMS, CHAMP1, RAB5IF | MGLL 2648/4885PTGS1 2733/4885PTGS2 2989/4885 |
| US-20140274951-A1 | LIGAND-THERAPEUTIC AGENT CONJUGATES, SILICON-BASED LINKERS, AND METHODS FOR MAKING AND USING THEM | CD44, CD47, SELPLG | MGLL 4065/4885PTGS1 4025/4885PTGS2 4195/4885 |
| US-11141489-B2 | Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acid | GLP1R, GIPR, GCGR | MGLL 413/4885PTGS1 1526/4885PTGS2 2286/4885 |
| US-20140322247-A1 | CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF | MKI67, CCNI, PA2G4 | MGLL 4070/4885PTGS1 3295/4885PTGS2 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.